Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts

被引：36

作者：

Okabe, Teruo ^{[1
]}

Lindsay, Joseph ^{[1
]}

Buch, Ashesh N. ^{[1
]}

Steinberg, Daniel H. ^{[1
]}

Roy, Probal ^{[1
]}

Slottow, Tina L. Pinto ^{[1
]}

Smith, Kimberly ^{[1
]}

Torguson, Rebecca ^{[1
]}

Xue, Zhenyi ^{[1
]}

Satler, Lowell F. ^{[1
]}

Kent, Kenneth M. ^{[1
]}

Pichard, Augusto D. ^{[1
]}

Weissman, Neil J. ^{[1
]}

Waksman, Ron ^{[1
]}

机构：

[1] Washington Hosp Ctr, Cardiovasc Res Inst, Washington, DC 20010 USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2008年 / 102卷 / 05期

关键词：

D O I：

10.1016/j.amjcard.2008.04.041

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Conflicting data exist regarding an advantage of drug-eluting stents (DES) over bare metal stents (BMS) in catheter-based treatment of saphenous vein graft (SVG) stenoses. This study was undertaken to compare the efficacy of these modalities in that lesion subset. The DES group consisted of 138 cases with 183 lesions (sirolimus-eluting stents, n = 117; paclitaxel-eluting stents, n = 66) and the BMS group consisted of 344 cases with 478 lesions that were followed to 1 year. We examined a composite end point that comprised death, Q-wave myocardial infarction, and target lesion revascularization. More BMS were deployed per patient (p < 0.001) and the diameters of BMS deployed was significantly greater (p < 0.001). Peak postprocedure values of creatine kinase-MB (p = 0.003) and troponin I (p = 0.05) were higher in BMS. At 1 year there was no significant superiority of DES over BMS with regard to hard end points (death and Q-wave myocardial infarction). In conclusion, this study indicates that both DES and BMS for SVG disease provide acceptably safe and efficacious results, but unlike the case in native coronary arteries, DES use does not reduce the frequency of the need for repeat revascularization. (C) 2008 Elsevier Inc. All rights reserved.

引用

页码：530 / 534

页数：5

共 20 条

[11] A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. [J].

Morice, M ;

Serruys, PW ;

Sousa, JE ;

Fajadet, J ;

Hayashi, EB ;

Perin, M ;

Colombo, A ;

Schuler, G ;

Barragan, P ;

Guagliumi, G ;

Molnar, F ;

Falotico, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (23) :1773-1780

[12] Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia - AWESOME randomized trial and registry experience with post-CABG patients [J].

Morrison, DA ;

Sethi, G ;

Sacks, J ;

Henderson, WG ;

Grover, F ;

Sedlis, S ;

Esposito, R .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 40 (11) :1951-1954

[13] Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery [J].

Moses, JW ;

Leon, MB ;

Popma, JJ ;

Fitzgerald, PJ ;

Holmes, DR ;

O'Shaughnessy, C ;

Caputo, RP ;

Kereiakes, DJ ;

Williams, DO ;

Teirstein, PS ;

Jaeger, JL ;

Kuntz, RE .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (14) :1315-1323

[14] Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries:: double-blind, randomised controlled trial (E-SIRIUS) [J].

Schofer, J ;

Schlüter, M ;

Gershlick, AH ;

Wijns, W ;

Garcia, E ;

Schampaert, E ;

Breithardt, G .

LANCET, 2003, 362 (9390) :1093-1099

[15] Coronary angioplasty versus repeat coronary artery bypass grafting for patients with previous bypass surgery [J].

Stephan, WJ ;

OKeefe, JH ;

Piehler, JM ;

McCallister, BD ;

Dahiya, RS ;

Shimshak, TM ;

Ligon, RW ;

Hartzler, GO .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1996, 28 (05) :1140-1146

[16] A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease [J].

Stone, GW ;

Ellis, SG ;

Cox, DA ;

Hermiller, J ;

O'Shaughnessy, C ;

Mann, JT ;

Turco, M ;

Caputo, R ;

Bergin, P ;

Greenberg, J ;

Popma, JJ ;

Russell, ME .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (03) :221-231

[17] Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention [J].

Tardiff, BE ;

Califf, RM ;

Tcheng, JE ;

Lincoff, AM ;

Sigmon, KN ;

Harrington, RA ;

Mahaffey, KW ;

Ohman, EM ;

Teirstein, PS ;

Blankenship, JC ;

Kitt, MM ;

Topol, EJ .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (01) :88-96

[18] Immediate and one-year outcome of percutaneous intervention of saphenous vein graft disease with paclitaxel-eluting stents [J].

Tsuchida, K ;

Ong, ATL ;

Aoki, J ;

van Mieghem, CAG ;

Rodriguz-Granillo, GA ;

Valgimigli, M ;

Sianos, G ;

Regar, E ;

McFadden, EP ;

van Der Giessen, WJ ;

de Feyter, PJ ;

de Jaegere, PPT ;

van Domburg, RT ;

Serruys, PW .

AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (03) :395-398

[19] Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts [J].

Vermeersch, Paul ;

Agostoni, Pierfrancesco ;

Verheye, Stefan ;

Van den Heuvel, Paul ;

Convens, Carl ;

Van den Branden, Frank ;

Van Langenhove, Glenn .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (03) :261-267

[20] Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts - Six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC trial [J].

Vermeersch, Paul ;

Agostoni, Pierfrancesco ;

Verheye, Stefan ;

Van den Heuvel, Paul ;

Convens, Carl ;

Bruining, Nico ;

Van den Branden, Frank ;

Van Langenhove, Glenn .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (12) :2423-2431

← 1 2 →